"Nephrosis, Lipoid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
- Nephrosis, Lipoid
- Lipoid Nephroses
- Lipoid Nephrosis
- Nephroses, Lipoid
- Minimal Change Glomerulopathy
- Minimal Change Disease
- Change Diseases, Minimal
- Disease, Minimal Change
- Diseases, Minimal Change
- Minimal Change Diseases
- Nephropathy, Minimal Change
- Minimal Change Nephropathies
- Minimal Change Nephropathy
- Nephropathies, Minimal Change
- Glomerulopathy, Minimal Change
- Glomerulopathies, Minimal Change
- Idiopathic Minimal Change Nephrotic Syndrome
Glomerulonephritis, Minimal Change
- Glomerulonephritis, Minimal Change
- Glomerulonephritides, Minimal Change
- Minimal Change Glomerulonephritides
- Minimal Change Glomerulonephritis
Below are MeSH descriptors whose meaning is more general than "Nephrosis, Lipoid".
Below are MeSH descriptors whose meaning is more specific than "Nephrosis, Lipoid".
This graph shows the total number of publications written about "Nephrosis, Lipoid" by people in Harvard Catalyst Profiles by year, and whether "Nephrosis, Lipoid" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Nephrosis, Lipoid" by people in Profiles.
A Novel Mouse Model of Idiopathic Nephrotic Syndrome Induced by Immunization with the Podocyte Protein Crb2. J Am Soc Nephrol. 2022 11; 33(11):2008-2025.
Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J Am Soc Nephrol. 2022 01; 33(1):238-252.
AMPK mediates regulation of glomerular volume and podocyte survival. JCI Insight. 2021 10 08; 6(19).
Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021 08; 100(2):463-464.
Minimal change disease concurrent with acute interstitial nephritis after long-term use of sorafenib in a patient with renal cell carcinoma. CEN Case Rep. 2021 05; 10(2):287-293.
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. Arthritis Rheumatol. 2021 02; 73(2):347-354.
Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. Adv Chronic Kidney Dis. 2020 09; 27(5):365-376.
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmun Rev. 2020 Nov; 19(11):102671.
Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies?. Clin Nephrol. 2020 Sep; 94(3):117-126.
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol. 2020 04 15; 21(1):134.